|Mr. Mark Mallon||CEO & Director||2.57M||N/A||1963|
|Mr. Thomas A. McCourt||Pres||974.02k||959.45k||1957|
|Ms. Gina R. Consylman CPA||CFO, Sr. VP & Treasurer||1.1M||N/A||1973|
|Mr. Brian M. Cali||Co-Founder and Sr. VP of R&D Strategy & External Innovation||N/A||N/A||N/A|
|Mr. G. Todd Milne||Co-Founder and VP of sGC R&D||N/A||N/A||N/A|
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.
Ironwood Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 4. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 7; Compensation: 7.